Leap Therapeutics Reveals Promising DeFianCe Study Results

Leap Therapeutics ( (LPTX) ) just unveiled an announcement.

On October 20, 2025, Leap Therapeutics announced the final results from Part B of its DeFianCe study, presented at the ESMO Congress 2025. The study showed that sirexatamab, in combination with bevacizumab and chemotherapy, significantly improved progression-free survival (PFS) and overall survival (OS) in patients with microsatellite stable colorectal cancer and high DKK1 levels. The results suggest that sirexatamab could be a valuable addition to CRC treatment, with plans for further development and regulatory engagement.

The most recent analyst rating on (LPTX) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.

Spark’s Take on LPTX Stock

According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.

Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.

To see Spark’s full report on LPTX stock, click here.

More about Leap Therapeutics

Leap Therapeutics is a biotechnology company focused on developing targeted and immuno-oncology therapeutics. Its pipeline includes sirexatamab (DKN-01), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Average Trading Volume: 3,360,270

Technical Sentiment Signal: Sell

Current Market Cap: $22.85M

For detailed information about LPTX stock, go to TipRanks’ Stock Analysis page.